(Q24803870)

volume

5

0 references

issue

1

0 references

page(s)

8

0 references

cites work

Noninferiority trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Declaration of Helsinki should be strengthened

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Concept of true and perceived placebo effects

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Placebo orthodoxy in clinical research. I: Empirical and methodological myths

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

The continuing unethical use of placebo controls

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

7 April 2017

1 reference

https://api.crossref.org/works/10.1186/1468-6708-5-8

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Demonstrating effectiveness in a post-placebo era.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

28 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

28 September 2017

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

7 January 2021

inferred from DOI database lookup

Ethical issues in the design and conduct of randomised controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

When placebo controlled trials are essential and equivalence trials are inadequate

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

GR106642X: a new, non-ozone depleting propellant for inhalers.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Statistics notes: Absence of evidence is not evidence of absence

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

From methodology to ethics and from ethics to methodology.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Beta blockade during and after myocardial infarction: an overview of the randomized trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

The design of future cost-benefit studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Points to consider on switching between superiority and non-inferiority

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Practical issues in equivalence trials.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

Trials to assess equivalence: the importance of rigorous methods

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

30 May 2018

The qualification period

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

NIH promotes use of lower cost drugs for hypertension

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Placebo and EU guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

The ethics of clinical research in the Third World

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Adjusting Europe's drug regulation to public health needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Claims of equivalence in medical research: are they supported by the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Divergent traditions in analgesic clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Scientific and ethical issues in equivalence trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

The impact of compliance in pharmacokinetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Torsades de pointes caused by Mibefradil

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Matters of the heart: assessing the cardiovascular safety of new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=514891

The cost-benefit approach

28 November 2018

1 reference

12 December 2020

Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology

1 reference

12 December 2020

Treatment for Newly Diagnosed Hypertension: Patterns of Prescribing and Antihypertensive Effectiveness in the UK

1 reference

12 December 2020

Absence of evidence is not evidence of absence

1 reference

12 December 2020

The pharmaceutical industry and health reform: lessons from Europe

1 reference

12 December 2020

Active-control equivalence trials and antihypertensive agents

1 reference

12 December 2020

Utility and pitfalls of some statistical methods in active controlled clinical trials

1 reference

12 December 2020

Therapeutic bioequivalency study of brand name versus generic carbamazepine

1 reference

12 December 2020

Design and interpretation of equivalence trials

1 reference

12 December 2020

Equivalence and noninferiority trials

1 reference

12 December 2020

Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. CPMP Working Party on Efficacy of Medicinal Products Note for Guidance III/3630/92-EN

1 reference

12 December 2020

1 reference

12 December 2020

Dangers of anaesthesia, 1884

1 reference

https://api.crossref.org/works/10.1186%2F1468-6708-5-8

7 January 2021